{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"104","value":"2390"},{"groupId":"OG001","spread":"58.2","value":"914"},{"groupId":"OG002","spread":"50.7","value":"1061"},{"groupId":"OG003","spread":"197.3","value":"1193"},{"groupId":"OG004","spread":"62.1","value":"722"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"30"}],"units":"Participants"}],"description":"Plasma concentrations of carfilzomib were determined by a validated liquid chromatography tandem mass spectrometry method. Concentration values that were below the lower limit of quantification of 0.1 ng/mL were set to zero. Treatment groups receiving the same dose (e.g. 20 mg/m²) were combined for Day 1 analyses.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with solid tumors received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Day 1.","id":"OG000","title":"ST: CFZ 20 mg/m² Bolus"},{"description":"Participants with solid tumors received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Day 1.","id":"OG001","title":"ST: CFZ 20 mg/m²"},{"description":"Participants with solid tumors received carfilzomib 36 mg/m² administered by intravenous infusion over 30 minutes on Day 1.","id":"OG002","title":"ST: CFZ 36 mg/m²"},{"description":"Participants with solid tumors received carfilzomib 45 mg/m² administered by intravenous infusion over 30 minutes on Day 1.","id":"OG003","title":"ST: CFZ 45 mg/m²"},{"description":"Participants with multiple myeloma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Day 1.","id":"OG004","title":"MM: CFZ 20 mg/m²"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Safety population with available pharmacokinetic (PK) data. PK analyses were conducted in solid tumor and multiple myeloma groups only and were not conducted for lymphoma or participants enrolled under Amendment 4 (CFX + dexamethasone).","reportingStatus":"POSTED","timeFrame":"Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.","title":"Maximum Observed Plasma Concentration of Carfilzomib","type":"SECONDARY","unitOfMeasure":"ng/mL"}